Trial reportBritish journal of haematology2014
Quantification of clonal circulating plasma cells in relapsed multiple myeloma.
Trial report in British journal of haematology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Circulating plasma cells as a predictive biomarker in Multiple myeloma: an updated systematic review and meta-analysis.Annals of medicine · 2024Pooled it
- Pooled it
- Prognostic value of circulating plasma cells in patients with multiple myeloma: A meta-analysis.PloS one · 2017Pooled it
- Circulating tumour cells (CTCs) in haematological malignancies: Advances in biology and clinical relevance with a focus on multiple myeloma.British journal of haematology · 2026Review
- Enhanced Detection of Multiple Myeloma Cells by Next-Generation Flow Cytometry Following Density Gradient Medium Separation.European journal of haematology · 2026Article
- Article
- Liquid biopsy by analysis of circulating myeloma cells and cell-free nucleic acids: a novel noninvasive approach of disease evaluation in multiple myeloma.Biomarker research · 2023Review
- High-risk multiple myeloma predicted by circulating plasma cells and its genetic characteristics.Frontiers in oncology · 2023Article
- Review
- Enrichment-Free Single-Cell Detection and Morphogenomic Profiling of Myeloma Patient Samples to Delineate Circulating Rare Plasma Cell Clones.Current oncology (Toronto, Ont.) · 2022Article
- Monitoring multiple myeloma in the peripheral blood based on cell-free DNA and circulating plasma cells.Annals of hematology · 2022Article
- Advances in the molecular characterization of multiple myeloma and mechanism of therapeutic resistance.Frontiers in oncology · 2022Review
- Is Quantification of Measurable Clonal Plasma Cells in Stem Cell Grafts (gMRD) Clinically Meaningful?Frontiers in oncology · 2022Review
- Prognostic and predictive biomarker developments in multiple myeloma.Journal of hematology & oncology · 2021Review
- Next-Generation Biomarkers in Multiple Myeloma: Understanding the Molecular Basis for Potential Use in Diagnosis and Prognosis.International journal of molecular sciences · 2021Review
- Blood-based risk stratification for pre-malignant and symptomatic plasma cell neoplasms to improve patient management.American journal of cancer research · 2021Article
- Circulating Plasma Cells as a Biomarker to Predict Newly Diagnosed Multiple Myeloma Prognosis: Developing Nomogram Prognostic Models.Frontiers in oncology · 2021Article
- Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma.Leukemia · 2020Article
- Treatment of relapsed and refractory multiple myeloma.Blood research · 2020Review
- Detection of Circulating Tumor Plasma Cells in Monoclonal Gammopathies: Methods, Pathogenic Role, and Clinical Implications.Cancers · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
The presence of clonal circulating plasma cells (cPCs) remains a marker of high-risk disease in newly diagnosed multiple myeloma (MM) patients. However, its prognostic utility in MM patients with previously treated disease is unknown. We studied 647 consecutive patients with previously treated MM seen at the Mayo Clinic, Rochester who had their peripheral blood evaluated for cPCs by multi-parameter flow cytometry. Of these patients, 145 had actively relapsing disease while the remaining 502 had disease that was in a plateau and included 68 patients in complete remission (CR) and 434 patients with stable disease. Patients with actively relapsing disease were more likely to have clonal cPCs than those in a plateau (P < 0·001). None of the patients in CR had any clonal cPCs detected. Among patients whose disease was in a plateau, the presence of clonal cPCs predicted for a worse median survival (22 months vs. not reached; P = 0·004). Among actively relapsing patients, the presence of ≥100 cPCs predicted for a worse survival after flow cytometry analysis (12 months vs. 33 months; P < 0·001). Future studies are needed to determine the role of these findings in developing a risk-adapted treatment approach in MM patients with actively relapsing disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.